Introduction. Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers.
INTRODUCTION
Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates glucosedependent insulin secretion and can modify cardiovascular risk biomarkers such as hs-CRP, IL-6, and TNF-α [1] . Another analogue of GLP-1 exenatide has a potent and rapid anti-inflammatory effect with a significant reduction in reactive oxygen species generation and the mRNA expression of several inflammatory mediators (TNF-α, JNK-1, TLR-2, TLR-4, IL-1, SOCS-3) in mononuclear cells [2] . The inhibitor of the enzyme dipeptidyl peptidase IV, which degrades GLP-1, led to the decrease of TLR-2, IKKb expression and nuclear factor-kB (NF-kB)  binding [3] .
Due to these data L can influence NF-kB inflammatory cascade, but the mechanisms of antiinflammatory activities of L remain to be determined. One possible way that L can influence an activity of some deacetylases because L modified an activity of Sirtuin 1(SIRT1) in several cell types in animal models [4] [5] [6] [7] [8] . On the other hand, recent evidences strongly suggest that SIRT1 up-regulation may serve as a potent therapeutic approach against development and progression of diabetic complications [9] . Taking together these data suggests that L can provide anti-inflammatory activity connected with an inhibition of NF-kB pathway mediated by upregulation of SIRT1.
The aim of this study was to investigate L effects directed on pro-inflammatory NF-kB pathway and expression of SIRT1 in obese patients with type 2 diabetes mellitus (DM).
MATERIALS AND METHODS
This is a single-center, add-on prospective study. Fifteen obese patients with type 2 DM with a glycosylated hemoglobin (HbA1c) between 6.04 and 9.7% participated in this study. None of the subjects had any microvascular or macrovascular complications of diabetes. All patients were on stable doses of oral antidiabetic medications and had stable weight for 4 weeks before the study. All patients were on metformin (1-2 g/d), and 4 patients were on sulfonylureas (glymepiride 2 mg/d). The dose of statins and angiotensin converting enzyme inhibitors were not changed during the study. None of the subjects were on thiazolidinediones, antioxidants, or nonsteroidal anti-inflammatory drugs. Patients' demographic data are summarized in Table 1 . All patients met with the dietitian and certified diabetes educator on 4 weeks before the study. General dietary recommendations as per American Diabetes Association guidelines were made to all subjects. All patients received L 1.2 mg daily add-on to stable therapy for 6 weeks. Blood samples were collected before, 6 weeks after start of treatment and 6 weeks after the stop of L after an overnight fast. The protocol was approved by the Ethic Committee of the University. An informed consent was signed by all subjects. 
MNC isolation
Blood samples were collected in Na-EDTA and carefully layered on ficoll-urograpfine gradient. Samples were centrifuged and the MNC band was harvested and washed twice with Hanks' balanced salt solution. This method provides yields greater than 95% MNC in the preparation. 
Quantification of TLR-2, TLR

Plasma measurements
Glucose, ceruloplasmin and total cholesterol concentrations were measured in plasma by the photometric method. HbA1c concentration was measured by kits from BioSystems, Spain.
Statistical analysis
Statistical analysis was conducted using Sigma Stat software (SPSS Inc., Chicago, IL). All data are represented as mean ± SE. Paired t test and Student's t test were used where appropriate.
RESULTS
Baseline characteristics
Fifteen subjects received L -eleven females and four males, mean age 54.56 ± 7.15 yr; mean body mass index (BMI) 41.07 ± 6.38 kg/m 2 , mean HbA1c 7.79 ± 0.78% ( Table 1 .
Effect of L on metabolic indices
BMI decreased within 6 weeks of the administration of L 1.2 mg daily to 38.94 ± 4.93 kg/m 2 (p = 0.006) (Fig. 1,A) . After the treatment with L, HbA1c fell significantly from 7.79 ± 0.78 to 7.12 ± 0.85 % (P = 0.0050) (Fig. 1, B) , fasting glucose -from 8.46 ± 1.80 to 6.73 ± 1.05 mmol/L (P = 0.0071), total cholesterol -from 6.62 ± 1.34 to 6.07 ± 0.74 mmol/L (P = 0.0172), ceruloplasmin -from 253.92 ± 16.54 to 236.38 ± 16.09 mg/L (P = 0.0000). Blood pressure decreased significantly: systolic blood pressure -from 150.0 ± 12.5 to 140.9 ± 8.0 (P = 0.0015) and diastolic blood pressure -from 94.1 ± 7.0 to 87.9 ± 4.0 (P = 0.0015) mm Hg (Table 1) .
At 6 weeks after the stop of L, BMI decreased from 38.94+4.93 to 37.62 ± 4.70 kg/m 2 (P = 0.0004), HbA1c fell significantly from 7.12 ± 0.85 to 6.66 ± 0.68% (P = 0.0030) (Fig. 1) , fasting glucose -from 6.73 ± 1.05 to 5.70 ± 0.74 mmol/L (P = 0.0008), total cholesterol -from 6.07 ± 0.74 to 5.52 ± 0.32 mmol/L (P = 0.0043), ceruloplasminfrom 236.38 ± 16.09 to 227.58 ± 22.41mg/L (P = 0.0145). Blood pressure decreased insignificantly.
Effect of L on TLR-2, TLR-4, NOD-1, TNFα, IL-2, IkB and SIRT1 gene expressions
Peripheral blood MNCs had a relatively low expression of TNFα (0.11 ± 0.12), IL-2(0.14 ± 0.2), IkB (0.06 ± 0.06) ( Table 3) , TLR-2 (0.421 ± 0.126), NOD-1 (0.047 ± 0.027), and SIRT1 (0.008 ± 0.008) (Fig. 2 A, B, C, D ) genes in comparison with the housekeeping gene.TLR-4 gene expression was higher (1.658 ± 1.211).
Table 3
The mRNA expression of TNFα, IL-2, IkB at baseline, after 6 weeks of 1. 
DISCUSSION
In this pilot clinical investigation we provided new data that L can inhibit proinflammatory NF-kB pathway by increased SIRT1 expression in obese patients with type 2 DM improving metabolic profile.
Several years ago the conception for permanent activation of nuclear factor kB as a possible typical pathological process was provided supposing that NF-kB is the key molecule in the initiation and formation of "a vicious circle -insulin resistanceinflammation -atherosclerosis" [10] .
An inflammatory process in the pathogenesis of insulin resistance in obesity and type 2 DM coupled to the IKKb/NF-kB pathway as a molecular mediator of insulin resistance and pharmacological target for insulin sensitization [11] .
Our data support this point of view demonstrating that obese patients with type 2 DM had the high expression of TLR-4. TLR-4 is the receptor for endotoxin and some lipoproteins. Lipopolysaccharide-induced clinical inflammatory response were mediated by TLR-4 binding and led to the secretion of TNF-α. TNF-α is a NF-kB-induced gene product like IL-2, ceruloplasmin, etc.
Incretins or inhibitors dipeptidyl peptidase-IV (DPP-IV), such as exenatide, sitagliptin, liraglutide, are currently being used in the treatment of type 2 DM [12; 13; 14]. Inhibitor DPP-IV sitagliptine exerted a potent anti-inflammatory effect due to suppression of intranuclear NF-kB binding and the expression of IKKb, CCR-2, TLR-2 and CD26 [3] .
GLP-1 suppressed inflammation (soluble intercellular adhesion molecule-1 and interleukin-6) in type 1 DM patients [15] . In animal model of allergic inflammation it was shown that GLP-1 inactivates NF-kB possibly through PKA [16] .
L as GLP-1 analogue exerts an anti-inflammatory effect on vascular endothelial cells by increasing nitric oxide production and exerts antiinflammatory action [12, 17] . L had a strong antiinflammatory effect on cultured human aortic endothelial cells due to its ability to increase intracellular Ca 2+ and activate CAMKKβ, which in turn activates AMPK [18] .
Our data showed that L decreased the mRNA expression of TNF-α, IkB, TLR2, TLR4, in peripheral blood MNC. These findings support the antiinflammatory activity of L directed to the NF-kB pathway and to the pattern recognition molecules.
TNF-α and TLR-4 induce serine phosphorylation of IRS-1 and are involved in insulin resistance pathogenesis [19] . Thus, L may be a potential insulin sensitizer. Recent data showed that liraglutide anti-inflammatory effects depended on SIRT6 expression. Both endothelial progenitor cells and endothelial cells treated with high glucose (25 mmol/L) in the presence of GLP-1 (100 nmol/L liraglutide) presented a greater SIRT6 and a lower NF-kB expression as compared with cells treated only with high glucose. These findings establish the involvement of SIRT6 in the inflammatory pathways of diabetic atherosclerotic lesions and suggest its possible positive modulation by incretin, the effect of which is associated with morphological and compositional characteristics of a potential stable plaque phenotype [20] .
From our point of view not only SIRT6 realized liraglutide effects but also SIRT1. Sirtuin 1 (SIRT1), a class III histone/protein deacetylase, is associated with aging and metabolism through maintaining inflammation via NF-kB. The upregulation of NF-kB transcriptional activity and pro-inflammatory cytokine mRNA expression by p65 subunit of NF-kB and lipopolysaccharide were suppressed by SIRT1 [21] . Because of the central role of NF-kB in cytokine-mediated pancreatic β-cell damage, it was postulated that SIRT1 might work in pancreatic β-cell damage models [22] .
As a deacetylase target of Sirt1, nuclear factor-kappa B (NF-kB) regulates the significant cell biological activity including cell cycle, apoptosis, adhesion and angiogenesis through interacting with its downstream genes [23] . It has been reported that Sirt1 could deacetylate p65 subunit of NF-kB at lysine 310 to inhibit its transcription physically [24] .
In the animal models it was shown that L influenced SIRT 1 activity in obesity-induced chronic kidney injury [5] , in TNF-a and hypoxiastimulated H9c2 cells [6] , in the infarcted heart [25] , in non-alcoholic fatty liver disease [26] , in streptozotocin-induced diabetic rats [7] , and in the brain of type 2 diabetes rats [8] .
Our data had shown the strong and long lasting effect of liraglutide on the expression of SIRT-1 in patients. Liraglutide increased SIRT-1 expression significantly after 6 weeks of treatment and this effect was observed during 6 weeks after the end of treatment. Moreover, we observed the further decreasing of BMI, HbA1c, fasting glucose, total cholesterol, and ceruloplasmin. Taking into consideration the fact that SIRT-1 is involved in the epigenetic regulation of pathological pathways in many diseases, such as type 2 DM [9, 26, 27] , we suppose that such liraglutide effect is mediated by epigenetic regulation.
Our investigation has several limitations. The data obtained are limited by the add-on design of clinical investigation, and further placebo-controlled trials are needed. A stronger calculation could be performed for statistical analysis to ensure the significance of L influence on SIRT1 expression in obese patients with type 2 DM.
Recent data contributed to epigenetic treatment of type 2 DM targeted on SIRT1-regulated and relevant for diabetes genes by L. SIRT1-targeted L activity found in peripheral blood mononuclear cells should be proved in other metabolic active tissues in patients with type 2 DM. The tight control of NF-kB pathway by SIRT1 needs further investigations.
CONCLUSIONS
Liraglutide exerts an anti-inflammatory effect as reflected in decreasing of TNF-α, IkB, TLR2, TLR4, NOD1 mRNA within 6 weeks of treatment in peripheral blood mononuclear cells and over the period of 6 weeks after the end of treatment. Plasma ceruloplasmin, total cholesterol and fasting glucose concentrations also fall significantly. Long lasting effects of liraglutide can be mediated by epigenetic regulation of NF-kB pathway by SIRT-1. Liraglutide may therefore be potentially antiatherogenic and may have the ability of insulin sensitizer. 
